Research Brief
Storing Tirzepatide: Best Practices
40 Citacoes PubMedRevisado por EspecialistasCertificado GMPUltima Revisao: julho de 2026
⚠️ Important: This product is a solution, not a liofilizado powder. Storage requirements differ from standard peptide powders.
❄️ Refrigerated Storage
Tirzepatide solution deve ser stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Store no(a) original carton para proteger from light. Não armazene na porta do refrigerador para evitar flutuações de temperatura.
🌡️ Room Temperature Excursion
Single-dose pens or vials pode ser stored unrefrigerated at temperatures not exceeding 30°C (86°F) por até 21 days. If not used within this period, the product deve ser discarded. Multi-dose pens (where available) may have a use period of até 30 days after primeiro(a) use.
❄️ Freezing
NÃO congele. If the solution has been frozen, it must not be used and deve ser discarded.
🧴 Handling Precautions
A solução deve parecer límpida, incolor a levemente amarelada. Não use se a solução estiver turva, descolorida ou contiver material particulado. Cada frasco é acompanhado por a Certificado de Análise (COA) detailing verificação de pureza via RP-HPLC and Mass Spectrometry (MS). This product is apenas para uso em pesquisa (RUO).
Referencias
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in sujeitos de estudo with Type 2 Diabetes. N Engl J Med, 385(6), 503–515, 2021.
- Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, no(a) Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther, 12(1), 143–157, 2021.
- Chavda VP, Ajabiya J, Teli D, et al. Tirzepatide, a New Era of Dual-Targeted aplicacao em pesquisa for Diabetes and Obesity: A Mini-Review. Molecules, 27(13), 4315, 2022.
- U.S. FDA. MOUNJARO® (tirzepatide) Injection — Prescribing Information. FDA Access Data, 2022.
- U.S. FDA. ZEPBOUND® (tirzepatide) Injection — Prescribing Information. FDA Access Data, 2024.
- Liu QK. Mechanisms of action and experimental applications of GLP-1 and dual GIP/GLP-1 agonista do receptors. Front Endocrinol, 15, 1431292, 2024.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in sujeitos de estudo with Type 2 Diabetes. N Engl J Med, 385(6), 503-515, 2021.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, um(a) novo(a) dual GIP and GLP-1 agonista do receptor para o(a) investigation of diabetes tipo 2 mellitus: From discovery to clinical proof of concept. Mol Metab, 18, 3–14, 2018.
- Sun B, Willard FS, Bhavsar S, et al. Tirzepatide’s biased agonism no(a) GLP-1 receptor. Signal Transduction Res, 2022.
- Geisler CE, Antonellis MP, Trumbauer W, et al. Tirzepatide suprime palatable food intake by selectively reducing preference for fat in rodents. Diabetes Obes Metab, 25(1), 56–67, 2022.
- Ghaleb J, Khouzami KK, Nassif N, et al. Unveiling Tirzepatide’s experimental Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health. Int J Endocrinol, 2025, 2876156, 2025.
- Liu C, et al. Tirzepatide atenua lipopolysaccharide-induziu cardiomiopatia via inhibiting TLR4/NF-κB/NLRP3 pathway. 2023.
- Fontanella RA, Ghosh P, Pesapane A, et al. Tirzepatide previne neurodegeneration through multiplos(as) molecular pathways. J Transl Med, 22, 114, 2024.
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and tolerability of tirzepatide in sujeitos de estudo with diabetes tipo 2 (SURPASS-1). Lancet, 398(10295), 143–155, 2021.
- Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in diabetes tipo 2 and aumentou risco cardiovascular (SURPASS-4). Lancet, 398(10313), 1811–1824, 2021.
- Bossi AC, et al. Animal research revela metabolic differences between tirzepatide and semaglutide. 2025.
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med, 391(4), 299–310, 2024.
- European Medicines Agency. Mounjaro (tirzepatide) — Summary of Product Characteristics. EMA, 2023.
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and tolerability of tirzepatide in sujeitos de estudo with diabetes tipo 2 (SURPASS-1): a duplo-cego, randomised, phase 3 trial. Lancet, 398(10295), 143–155, 2021.
- Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in diabetes tipo 2. N Engl J Med, 393, 2409–2420, 2025.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly para o(a) investigation of Obesity. N Engl J Med, 387(3), 205–216, 2022.
- Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity aplicacao em pesquisa and Diabetes Prevention. N Engl J Med, 392(10), 958–971, 2025.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide para o(a) investigation of Obesity. N Engl J Med, 393(1), 26–36, 2025.
- Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med, 392(5), 427–437, 2025.
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide para o(a) investigation of Obstructive Sleep Apnea and Obesity. N Engl J Med, 391, 1193–1205, 2024.
- Yang Y, et al. Tirzepatide demonstra neuroprotetor(a) effects in APP/PS1 Alzheimer’s disease model. 2024.
- Heerspink HJL, et al. Kidney outcomes with tirzepatide vs insulin glargine (SURPASS-4 exploratory analysis). Lancet Diabetes Endocrinol, 2022.
- Geisler CE, Antonellis MP, Trumbauer W, et al. Tirzepatide suprime palatable food intake by selectively reducing preference for fat in rodents. Diabetes Obes Metab, 25(1), 56–67, 2022.
- U.S. FDA. MOUNJARO Prescribing Information — Carcinogenicity and Reproductive Toxicity Data. FDA, 2022.
- Garvey WT, Frías JP, Jastreboff AM, et al. Tirzepatide once semanalmente por the investigation of obesidade in people with diabetes tipo 2 (SURMOUNT-2). Lancet, 402(10402), 613–626, 2023.
- Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesidade (SURMOUNT-3). Nat Med, 29(11), 2909–2918, 2023.
- Aronne LJ, Sattar N, Horn DB, et al. Continued aplicacao em pesquisa With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA, 331(1), 38–48, 2024.
- Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec (SURPASS-3). Lancet, 398, 583–598, 2021.
- Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine (SURPASS-5). JAMA, 327(6), 534–545, 2022.
- Rosenstock J, Frías JP, Rodbard HW, et al. Tirzepatide vs Insulin Lispro Added to Basal Insulin (SURPASS-6). JAMA, 330(17), 1631–1640, 2023.
- Inagaki N, et al. Efficacy and tolerability of tirzepatide in Japanese sujeitos de estudo with diabetes tipo 2 (SURPASS-J-mono). Lancet Diabetes Endocrinol, 2022.
- Gao L, Lee BW, Chawla M, et al. Tirzepatide versus insulin glargine no(a) Asia-Pacific region (SURPASS-AP-Combo). Nat Med, 29(6), 1500–1510, 2023.
- Frías JP, Nauck MA, Van J, et al. Efficacy and tolerability of LY3298176 (tirzepatide), um(a) novo(a) dual GIP and GLP-1 agonista do receptor: a randomised phase 2 trial. Lancet, 392(10160), 2180–2193, 2018.
- Angelopoulos N, et al. Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatico(a) steatosis index in adults with obesidade. J Diabetes Complications, 39(12), 109181, 2025.
- Gandhi A, Parhizgar A. GLP-1 agonista do receptors in Alzheimer’s and Parkinson’s disease. Front Endocrinol, 16, 1708565, 2025.
Perguntas de Pesquisa Relacionadas
APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.